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ABSTRACT 
  
 Recent studies with Dengue (DEN) and West Nile (WN) viruses have focused 
on structural analyses, and host cellular and immunological responses to viral infection.   
In this project, various DEN and WN proteins were expressed in E. coli using 
recombinant expression plasmids. Expression was verified by RT-PCR and immunoblots.  
The expressed proteins will be used in the future to test T-cell reactivities against viral 
proteins. 
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BACKGROUND 
 
Flaviviruses 
The Flaviviridea family has a multitude of viruses that cause disease in humans. 
The International Committee of Taxonomy of Viruses (ICTV) has subdivided the 
Flaviviridea family into three genera: Flavivirus, Pestivirus, and Hepacivirus. 
Flaviviruses include 69 pathogens such as Dengue (DEN), West Nile (WN), and Yellow 
Fever viruses.  Some of these pathogens are dangerous arthropod-borne diseases, which 
cause millions of human illnesses a year.  Carriers are typically mosquitoes, sand flies, 
ceratopogonids, and ticks.  Several of these dangerous viruses are being studied for 
defense against bioterrorist attacks (Gaidos, 2002). The Pestivirus genus consists of three 
serotypes of bovine viral diarrhea, but there are no known human pathogens.  The 
Hepacivirus genus includes viruses such as Hepatitis C. 
The focus of this project is two pathogens in the flavivirus family, DEN and WN. 
Flavivirus genomes consist of monopartite linear, single stranded, positive sense RNA.  
Because of the positive sense RNA, the nucleic acid is directly capable of initiating 
infection in an appropriate host cell.  The virons are known to be spherical with a 
diameter of 40-65 nm (see Figure 1).   
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Figure 1:  First Diagram of the Structure of a Flavivirus.   
Purdue University and California Institute of Technology were the first to first to 
solve the three-dimensional structure of a Flavivirus, in this case DEN.  According 
to Richard Kuhn, a Purdue University researcher, the structure “reveals an 
architectural structure that is different from any other virus that has been 
seen”(Gaidos, 2002).  This illustration shows the E protein organizing itself to 
form a protective shell around the virus (Purdue University computer illustration). 
 
All members of the flavivirus family are transmitted by arthropods (mosquitoes 
and ticks). The virus is spread to humans by the bite of an infected female mosquito, but 
is not spread through contaminated body fluids.  Flaviviruses are capable of reproducing 
in their vector, which is very important for viral transmission because it allows the virus 
to pass from one host to the next (Flavivirus, 1999). 
 
Dengue Virus (DEN) 
Dengue fever is a vector-borne infectious disease from the tropical and 
subtropical urban areas of the world. The vector for DEN is mainly the Aedes aegypti 
mosquito, but sometimes Aedes albopictus. The Aedes aegypti mosquito is a daytime 
biting mosquito that usually only feeds on humans and it’s the most common DEN vector 
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(CDC Dengue Fever Home Page, 2005).  However, Aedes albopictus was responsible for 
the 2001 outbreak in Hawaii (Dengue Q&A, 2005). 
There are four different serotypes of DEN (DEN-1, DEN-2, DEN-3, and DEN-4), 
with genetic variation within each serotype. Some of the serotypes appear to be more 
virulent than others (Dengue Fever Slides, 2003).  Infection and recovery from one 
serotype only provides immunity for that specific serotype (Fact Sheet, 2003). However 
there is sometimes short-term cross-immunity against the other serotype, but this may 
only last for a couple of months (Dengue Fever Slides, 2003). An individual can 
experience four different DEN infections in a lifetime (Fact Sheet, 2003).  The severe 
form of infection usually occurs after a secondary infection (Tassaneetriethep et al, 
2003). Although this process is not fully understood, the generally accepted reason for 
this is an antibody-dependent enhancement process in which the antibodies induced in the 
primary infection facilitate the uptake of the secondary virus into white blood cells, and 
crossreacts with the serotype of the secondary infection contributing to a more severe 
form of infection (Se-Thoe et al, 2000).  
DEN transmission occurs as a cycle (Figure 2).  The cycle begins when a female 
mosquito feeds on a person who has already been infected with the virus, however, the 
mosquitoes are only infected by feeding on a viremic person with viruses present in the 
bloodstream. When a person is first infected with the virus, they go through an average 
incubation period of four to seven days but it can range from three to fourteen days. 
Viremia begins at the end of incubation, slightly before the onset of symptoms and lasts 
up to five days. The symptom onset lasts about three to ten days, which is several days 
after viremia has ended.  After the female mosquito has fed on a person during the 
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viremic period, that mosquito becomes infected with the virus. If that mosquito feeds on 
another person, it can transmit the virus to that person.  Viral transmission can only occur 
between mosquito and human, not from human to human. 
 
 
Figure 2: DEN Transmission Cycle.  A mosquito becomes infected with virus by feeding on 
viremic human #1 with virus in the bloodstream.  The infected mosquito then feeds on human #2 infecting 
him with the virus. When first infected with the virus, there is an intrinsic incubation period of four to 
seven days.  The viremic period occurs toward the end of the incubation period.  The onset of symptoms 
begins a day or two after viremia has begun, and lasts for three to ten days (CDC image). 
 
 
Once the virus is inoculated into a person by a mosquito, the virus targets specific 
organs, such as the lymph nodes and the liver. Then the virus infects white blood cells 
and lymphatic tissues, then is released into the bloodstream and spread throughout the 
body. 
The principal symptoms of DEN are high fever, severe headaches, backaches, 
joint pains, nausea and vomiting, eye pain, and rash.  The more severe symptoms include 
shock and hemorrhage.  Most DEN infections are mild, but some result in dengue 
hemorrhagic fever (DHF) or dengue shock syndrome (DSS).  DHF is characterized by a 
fever that last 2-7 days, followed by hemorrhagic manifestations, skin hemorrhage, 
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bleeding of gums or nose, and possible internal bleeding. When the small blood vessels 
(capillaries) become excessively permeable, fluid components escape from blood vessels, 
and this may cause failure to the circulatory system and shock, closely followed by death 
if the circulatory problem is not corrected (Dengue Q&A, 2005). 
There are millions of incidences of DEN worldwide.  It is estimated that there are 
50 to 100 million cases of DEN each year, and hundreds of thousands of DHF cases.  The 
average fatality rate for DHF is 5% (Fact Sheet, 2003). 
There is no specific treatment or medication for DEN. People who believe they 
have DEN are recommended to contact a physician, drink plenty of fluids, get plenty of 
rest, take pain relievers with acetaminophen, and avoid those that contain aspirin (Dengue 
Q&A, 2005).  Recently, a vaccine candidate for DEN was developed in Thailand.  
Research is also being conducted to develop a vaccine for secondary infection.  These 
vaccines are still in testing mode and will not become available for the public for another 
5 to 10 years (CDC Dengue Fever Home Page, 2005). 
 Much remains unknown about DEN virus.  Numerous clinical studies are in 
progress to further understand this virus.  Research is also focusing on the development 
of a tetravalent vaccine that will target all four serotypes of DEN.  There is also a need to 
develop rapid, sensitive, and specific diagnostic tests, and more effective prevention 
programs. 
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West Nile Virus 
 WN is a mosquito-borne virus from the temperate regions of the world, most 
recently in Europe and North America. WN transmission and infection (Figure 3) occurs 
when a female mosquito feeds on a nonhuman vertebrate (like a bird).  Then the infected 
mosquito feeds on a person and transmits the virus through its saliva. WN is primarily 
transmitted by members of the Culex mosquito species. 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Transmission Cycle of the WN Virus.  A mosquito becomes infected by feeding on 
a viremic reservoir host (usually a bird), and then the mosquito feeds on humans, domestic animals, or 
horses transmitting the virus to them.  The end hosts are known as incidental host because they do not 
develop infectious levels of viremia. Mosquitos are not capable of acquiring virus from incidental hosts, 
only from reservoir hosts (CDC image). 
 
WN is mainly spread from mosquito to vertebrate, rarely from vertebrate to 
vertebrate.  Mosquito’s are the primary vector, but the WN virus does not grow well 
there, so vertebrates are the host.  Hosts include humans, domestic animals (dogs, birds, 
and horses), and wild birds.  Humans and most other mammals are known to develop 
 11
infectious levels of viremia (virus in the bloodstream), but aren’t reservoir hosts.  They 
are usually known as incidental-hosts or “dead ends.”  If a mosquito feeds on a WN 
infected mammal, the mosquito doesn’t become infected with the virus, it merely passes 
it on to the next host bitten.  Because bird viremia is thousands of times higher than for 
humans, the mosquito usually acquires the virus from birds (West Nile Virus: 
Entomology, 2004). 
 A very small number of cases of WN are known to be spread through blood 
transfusion, organ transplants, and mother to child.  Mother to child instances occur 
during pregnancy and breastfeeding (West Nile Fact Sheet, 2004).  
 WN affects the central nervous system, and symptoms usually vary from case to 
case. WN is mainly known to cause encephalitis (inflammation of the brain) and 
meningitis (inflammation of the lining of the brain and the spinal cord).  About 80% of 
the people infected with the virus don’t show any symptoms.  The other 20% of people 
infected display symptoms including fever, headache, body aches, nausea, and vomiting.  
Sometimes symptoms include swollen lymph glands or skin rash on the chest, back, and 
stomach.  In the more severe cases of WN, symptoms include high fever, headaches, neck 
stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, vision 
loss, numbness, and paralysis.  In the milder cases, symptoms last a few days but can last 
longer.  In the more severe cases, symptoms last several weeks, and neurological effects 
can be permanent (West Nile Fact Sheet, 2004). 
 WN virus has become a predominant health risk in North America, primarily in 
the US.  According to the CDC, in 2002 there were 4,156 reported cases of WN human 
disease in the US.  3000 of these cases were central nervous system (CNS) disease cases, 
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and nearly 10% of them were fatal. In 2003, there were 9862 human cases of WN 
disease, and 264 cases were fatal (West Nile: Q&A, 2004). WN cases decreased in 2004, 
2470 cases were reported to the CDC and 88 of them were fatal (West Nile Virus: 
Statistics, Surveillance, and Control, 2005). Less than 1% of the people infected with WN 
develop encephalitis, which is the more severe symptom of WN.  Of those who develop 
encephalitis, 3% to 15% are fatality cases (West Nile Virus, 2002). 
 There is no specific treatment or therapy for WNV. People who develop 
symptoms are recommended to contact a physician, drink plenty of fluids and get plenty 
of rest.  In the more severe cases hospitalization is highly recommended.  Patients will 
need intravenous fluids and nutrition, airway management, ventilatory support, and 
prevention of secondary infections (West Nile Virus, 2002).  
 Much remains unknown about WNV.  Numerous clinical studies are in progress 
to further understand this virus.  Research is focusing on the development of a vaccine; 
rapid, sensitive, and specific diagnostic tests; and more effective prevention programs. 
 
Viral Proteins 
DEN and WN positive-stranded RNAs encode one polyprotein.  The polyprotein 
produces ten smaller proteins, three structural proteins and seven non-structural proteins. 
Structural proteins include: C, prM, and E. Non-structural proteins include: NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5 (Figures 4 and 5).  
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Figure 4: General Structure of the WN and DEN Genome.  Image illustrates the orientation 
of the genes in both DEN and WN.  Structural proteins come first [C (capsid), prM 
(membrane/premembrane), and E (envelope)], followed by the nonstructural proteins (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, and NS5).  
 
 
 
 
Figure 5: WN Replicon Structure.  WN replicon was used to target the nonstructural proteins. 
Replicon is a WN structure with deletion of structural proteins (deletion indicated by dotted lines).  
 
 The C protein is known as the capsid protein (or core protein), it’s a highly basic 
component of the nucleocapsid (Figure 6).   It is believed that the C protein functions in 
neutralizing the negatively charged viral RNA. There are two types of membrane (M) 
protein: prM and M. M resides in the extracellular mature virions, and prM resides in the 
intracellular mature virions.  M and prM are usually grouped together as the prM 
(membrane) protein (Chang, 1997).  prM is cleaved when the virus exits the cell, 
cleavage forms “pr” and “M” segments. The hydrophilic “pr” segment gets secreted into 
the extracellular medium; and “M” becomes a structural part of the lipid envelope 
(Campbell et al, 2002). Cleavage of prM results in the formation of mature virion with 
the ability to infect other cells (the non primary target cells). E is the envelope protein, 
the major part of the virion surface. E protein is associated with several biological 
functions, receptor binding and membrane fusion.  It is also a key target of the immune 
response to flaviviruses (Chang, 1997).  The E protein organizes itself to form a 
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protective shell around the virus; the shell serves as a cage for the genetic material inside 
the virus (Gaidos, 2002). The viral envelope and the membrane proteins are responsible 
for many of the important properties of the virus; host range, tissue tropism, replication, 
assembly, and stimulation of B and T cell immune responses (Campbell et al, 2002). 
 
 
Figure 6: Spherical Structure of Flaviviruses.  This image illustrates the spherical structure of 
flaviviruses and the general orientation of the structural proteins. The surface is usually smooth; its 
membrane is enclosed by a protein shell created by the envelope protein. (Universtat Wien image) 
 
The functions of the non-structural proteins are not as well classified as the 
functions of the structural proteins.  NS1 is expressed on the surface of infected cells, 
thus it is believed to be a target of the immune response. It’s also believed to be a soluble 
complement-fixing antigen (Chang, 1997).  NS2A works in tandem with NS3 as a 
protease. NS3 is a flavivirin protease.  NS2B is a flavivirin protease of regulatory 
subunits. NS4A is a catalytic subunit. NS5 is an RNA dependent RNA polymerase 
(Castle et al, 1986).  NS5 activities include RNA capping and viral RNA replication 
(Chang, 1997). In DEN-2, NS2A, NS4A, and NS4B have recently been associated with 
interferon antagonists (Munoz-Jordan et al, 2003). 
 
Gateway Technology 
Gateway Technology (Gateway) by Invitrogen Corp. was the cloning technology 
used in this project. It was used because of its highly efficient and rapid route to 
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functional analysis, protein expression, and cloning/subcloning of DNA segments. 
Gateway maximizes compatibility and flexibility, and it also minimizes the planning 
process. There is no need of restriction enzymes, gel purification, or ligation when using 
Gateway.  Gateway allows site specific recombination, transfer of one or more genes in 
one or more expression vectors in one experiment, yet any vector can be made 
compatible with the technology.   
One of Gateway’s greatest strengths is the capability of going directly from 
cloning to protein expression. It provides a rapid optimized recombinant protein 
expression. Gateway allows DNA segments to be transferred between different cloning 
vectors while maintaining its orientation and reading frames. This is possible because of 
the site specific recombination system of phage 1, which effectively replaces the use of 
restriction endonuclease and ligase.  A main goal of Gateway is to move gene(s) from 
one vector to another. There are various host systems in Gateway.  The best host system 
needs to be chosen for each specific experiment. Once the gene is cloned in a system, the 
sequence can be moved freely without concern of restriction enzyme site, reading frame, 
or insert orientation. 
The Gateway reactions are of high efficiency, fast, and simple.  They represent 
the in vitro version of integration and excision reactions. The two main Gateway 
reactions are the BP recombination reaction and the LR recombination reaction. 
 
BP Recombination Reaction 
An entry clone is created by using the BP recombination reaction.  The reaction 
transfers the gene of interest to a donor vector to create an entry clone.  The BP 
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recombination reaction is a lysogenic pathway, catalyzed by a bacteriophage λ integrase 
(Int) and E. coli Integration Host Factor (IHF) protein, that represent the BP Clonase 
enzyme mix.  The BP reaction is: 
attB x attP → attL x attR. 
The BP reaction is used to facilitate the recombination of attB DNA (i.e. PCR 
product or linearized expression clone) with an attP DNA (i.e. donor vector, pDONOR 
201 or pDONOR 221) to create an attL (substrate containing an entry clone). The BP 
reaction is catalyzed by the BP Clonase enzyme mix (Figure 7). 
 
 
 
Figure 7: The Gateway BP Recombination Reaction.  BP reaction facilitates the 
recombination of attB substrate with an attP substrate to create and attL clone.  Reaction is catalyzed by BP 
clonase (Gateway image).  
 
LR Recombination Reaction 
An expression clone is created by using the LR recombination reaction.  The 
reaction transfers the gene of interest to a destination vector to create an expression clone. 
The LR reaction is a lytic pathway, catalyzed by a bacteriophage λ integrase (Int), 
Excisionase (Xis), and E. coli Integration Host Factor (IHF) protein, each of which are 
included in the LR Clonase enzyme mix.  The LR reaction is: 
attL x attR → attB x attP 
The LR reaction is used to facilitate the recombination of attL substrate (entry 
clone) with a attR substrate (destination vector, pDEST17, pDEST26) to create an attB 
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(substrate containing an expression clone) clone.  The LR reaction is catalyzed by the LR 
Clonase enzyme mix (Figure 8). 
 
 
Figure 8: The LR Recombination Reaction.  The LR reaction facilitates the recombination of 
an attL substrate with an attR substrate to create and attB clone. The reaction is catalyzed by LR clonase 
(Gateway image).  
 
 
 
Site Length Found in 
AttB 25 bp Expression vectors Expression clone 
AttP 200 bp Donor vector 
AttL 100 bp Entry vector Entry clone 
AttR 125 bp Destination vector 
Table 1 Characteristics of att Sites.  attB1 sites only react with attP1 sites, attB2 sites 
only react with attP2 sites, attL1 sites only react with attR1 sites, and attL2 sites only react with 
attR2 sites. 
 
 
UMASS Center of Infectious Disease and Vaccine Research 
 The research for this project was conducted at the University of Massachusetts 
Medical School at the CIDVR department under the supervision of Irene Bosch.  
CIDVR’s mission “is to conduct research in and training for the study of the molecular 
basis of human diseases caused by infectious agents and the development of safe and 
effective vaccines against these agents (Center for Infectious Disease and Vaccine 
Research).”  The ultimate goal of the research at CIDVR is to understand the molecular 
mechanisms of disease pathogenesis, to define treatment of viral diseases, and develop 
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effective vaccines to prevent infection.   CIDVR’s clinical base research focuses on 
defining human T lymphocyte responses to viral infection and their role in protective 
immunity and disease pathogenesis. CIDVR’s research focuses on a variety of pathogens, 
flaviviruses (DEN, WN, yellow fever, and Japanese encephalitis virus), poxviruses 
(vaccinia virus), hantaviruses, influenza virus, hepatitis C virus, and HIV. 
 DEN and WN studies focus on defining immunological responses responsible for 
the increase severity of DEN disease during secondary infection. CIDVR collaborates 
with several international clinical studies, such as Thailand, Hawaii, Venezuela and 
Puerto Rico.  In Thailand, clinical studies are currently analyzing viral replication of 
DEN and the immune response of children with acute DEN infection.  They are also 
studying viral transmission and the disease in school children (Research Projects, 
CIDVR).   
 Dr. Bosch’s lab focuses on understanding the cellular response to viral infection 
from RNA viruses (DEN, WN, and yellow fever).  The main focus of the lab is monocyte 
infections and the exploration of inflammatory responses (Bosch Research, 2005).   
 Recently the lab researched the increased production of interleukin-8 in primary 
human monocytes and in human epithelial and endothelial cell lines after dengue virus 
challenge (Bosch et al, 2002). Another recent study was that dengue virus induces novel 
changes in gene expression of human umbilical vein endothelial cells (Warke et al, 
2003). 
Bosch’s lab also participates in the transfer of technology to third world countries 
for the advancement of science. There is a constant active participation in exchanges and 
activities outside the US (Bosch Research, 2005). 
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PROJECT OBJECTIVE 
 
The pathogenesis of Dengue (DEN) and West Nile (WN) virus are not well 
understood at this time, and therapeutic interventions do not exist.  The UMASS CIDVR 
has been focusing on understanding the cellular and immunological responses of these 
viruses to allow further understanding of the pathogenesis of these viruses and hopefully 
lead to the development of a treatment.  In order to understand a virus as a whole, one 
needs to learn about its components, thus the focus of this project is the viral proteins.   
Dr. Bosch’s lab is interested in cloning and expressing all the viral proteins for the DEN 
and WN viruses that will be used to test T-cell reactivities from infected patients, or to 
create antibodies to facilitate further analysis of protein function.  The goal of this MQP 
was to finish cloning and expressing several remaining viral proteins of DEN-2 and WN 
virus in bacterial and mammalian cells. 
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METHODS 
 
RT-PCR 
The reverse transcriptase-polymerase chain reaction (RT-PCR) technique was 
used to obtain the cDNA of several viral proteins. The viral RNA was provided by the 
CIDVR.  Forward and reverse primers were also provided by CIDVR.   
RT reactions were carried out in 20 µL reactions with 2 µL of 10x Buffer, 2 µL of 
dNTP (10 µM), 2 µL of specific forward primer, 2 µL of specific reverse primer, 1 µL of 
RT enzyme, 0.5 µL of RNase inhibitor, 7.5 µL of RNase free water, and 3 µL of RNA. 
The RT condition was 60 minutes at 37°C, 5 minutes at 93°C, and 4°C pause.  PCR 
reactions were carried out in 50 µL reactions with 23 µL of H2O, 15 µL of rtTH buffer, 1 
µL dNTP (10 µM), 2 µL of specific forward primer, 2 µL of specific reverse primer, 1.8 
µL of MgOAc (25 µM), 1 µL of rtTH polymerase, and 4 µL of cDNA from RT reaction. 
The PCR condition was 60 seconds at 93°C; then 35 cycles of 15 seconds at 94°C and 6 
minutes at 60°C; then 10 minutes at 72°C, and 4°C pause. 
 
RT-PCR Product Confirmation 
 A 1.5% agarose gel in TBE buffer was run with 20 µL of samples. 20 µL samples 
were prepared by combining 16 µL of RT-PCR product and 4 µL of loading dye. 2 µL of 
Molecular Weight Marker (100 bp ladder) was also loaded on a separate lane as a 
reference point.  
 
 
 21
Gel Extraction and DNA Purification 
 Positive DNA bands from RT-PCR product confirmations were excised from the 
gel for DNA purification.  The QIAGEN QIAquick Gel Extraction Kit, a 
microcentrifugation  protocol, was used for DNA extraction and purification. (See 
Appendix 3 for protocol.)  After gel extraction and DNA purification, samples were 
quantified by UV absorbance. 
 
BP Reaction 
 DNA mass values determined by UV absorbance were converted to fmol using 
the following formula: 
  
N represents the length of the DNA in base pair (bp). 
 In a 1.5 mL microcentrifuge tube the following components were mixed at room 
temperature: 1-10 µL (40-100 fmol) attB-PCR product, 2 µL pDONOR vector (150 
ng/µL), 4 µL 5X BP Clonase Reaction Buffer, and enough TE Buffer (pH 8.0) to make a 
solution volume of 16 µL.  The solution was mixed well, 4 µL of BP Clonase enzyme 
(stored at -80°C) was added to each sample, and samples were mixed again by vortexing. 
Samples were later incubated at 25°C for 1 hour.  After incubation, 2 µL of Proteinase K 
solution was added to each sample and incubated for 10 minutes at 37°C.  Then samples 
were transformed in competent E. coli cells. 
 
 22
 
Cell Transformation  
 An appropriate antibiotic based vector (entry vector or destination vector) was 
needed for transforming competent E. coli to select for entry clones.  Entry vectors were 
used in the BP reaction, which required kanamycin (KAN) antibiotic. Samples from the 
BP reaction were transformed in 50 µL of competent E. coli cells, DH5α or Top 10 cells.  
 1 µL of BP recombination reaction was added to E. coli.  Samples were incubated 
for 10 minutes on ice. After ice incubation, samples were heat shocked for 30 seconds at 
42°C.  Tubes were immediately transferred to ice after heat shock.  Then 450 µL of SOC 
medium was added to the samples.  Samples were then incubated for an hour at 37°C 
while shaking horizontally at 200 rpm.  After incubation, 100 µL of transformation was 
spread on pre-warmed KAN plates and incubated overnight at 37°C. Colonies were 
picked the following day and cultured overnight in LB-KAN medium.  
 
 
Plasmid Purification  
Plasmid DNA was prepared from the overnight cultures of the cell transformation 
using a QIAGEN QIAprep Miniprep Kit, microcentrifuge protocol. See Appendix 4 for 
protocol.  
 
Plasmid Confirmation 
 The purified plasmids were analyzed by polymerase chain reaction (PCR). 
PCR reactions were carried out in 50 µL with 39.5 µL of H2O, 5 µL of PCR buffer 
(MgCl2), 1 µL dNTP (10 mM), 1 µL of specific forward primer, 1 µL of specific reverse 
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primer, 1.5 µL of Taq Polymerase (5 µ/µL), and 2 µL of plasmid from Miniprep. The 
PCR condition was 60 seconds at 94°C; followed by a 28 cycles of 60 seconds at 58°C, 
45 seconds at 72°C, and 30 seconds at 94°C; then 60 seconds at 58°C, 10 minutes 72°C, 
and a 4°C pause.  
After PCR, plasmids were visualized by running a 1.5% agarose gel in TBE 
buffer.  20 µL samples were prepared by combining 16 µL of PCR product and 4 µL of 
loading dye. 2 µL of Molecular Weight Marker was also loaded on a separate lane as a 
reference point.  
Plasmids were also confirmed by sequencing.  Samples were sent to the UMASS 
sequencing center for sequencing.  Sequence confirmations were reviewed by Irene 
Bosch and Kris Giaya. 
 
LR Reaction 
 In a 1.5 mL microcentrifuge tube the following components were mixed at room 
temperature, 1-11 µL (100-220 ng/reaction) entry clone, 1-11 µL pDEST vector (300 
ng/reaction), 4 µL 5X LR Clonase Reaction Buffer, and enough TE Buffer (pH 8.0) to 
make solution volume 16 µL. The solution was mixed well, 4 µL of LR Clonase enzyme 
(stored at -80°C) was added to each sample, and samples were mixed well by vortexing. 
Reaction was incubated at 25°C for 1 hour.  After incubation, 2 µL of Proteinase K 
solution was added to each sample and incubated for 10 minutes at 37°C. Then samples 
were transformed into competent E. coli cells. 
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Cell Transformation  
 An appropriate antibiotic based vector (entry vector or destination vector) was 
needed for transforming competent E. coli to select for entry clones. Destination vectors 
were used in an LR reaction, which required ampicillin (AMP) antibiotic. Samples from 
the LR reaction were transformed in 50 µL of competent E. coli cells, (DH5α or Top 10).  
 1 µL of LR recombination reaction was added to competent E. coli.  Samples 
were incubated for 10 minutes on ice. After ice incubation, samples were heat shocked 
for 30 seconds at 42°C.  Tubes were immediately transferred to ice after heat shock.  
Then 450 µL of SOC medium was added to the samples.  Samples were then incubated 
for an hour at 37°C while shaking horizontally at 200 rpm.   After incubation, 100 µL of 
transformation was spread on pre-warmed AMP plates and incubated overnight at 37°C. 
Colonies were picked the following day and cultured overnight in LB-AMP medium.  
 
Plasmid Purification  
Plasmid DNA was isolated using a QIAGEN QIAprep Miniprep Kit.  See 
Appendix 4 for protocol.  
 
Plasmid Confirmation 
 The purified plasmids were analyzed by polymerase chain reaction (PCR). 
PCR reactions were carried out in 50 µL with 39.5 µL of H2O, 5 µL of PCR buffer 
(MgCl2), 1 µL dNTP (10 mM), 1 µL of specific forward primer, 1 µL of specific reverse 
primer, 1.5 µL of Taq Polymerase (5 µ/µL), and 2 µL of plasmid from Miniprep. The 
PCR condition was 60 seconds at 94°C; followed by a 28 cycles of 60 seconds at 58°C, 
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45 seconds at 72°C, and 30 seconds at 94°C; then 60 seconds at 58°C, 10 minutes 72°C, 
and a 4°C pause.  
After PCR, plasmids were visualized by running a 1.5% agarose gel in TBE 
buffer.  20 µL samples were prepared by combining 16 µL of PCR product and 4 µL of 
loading dye. 2 µL of Molecular Weight Marker was also loaded on a separate lane as a 
reference point.  
Plasmids were also confirmed by sequencing.  Samples were sent to the UMASS 
Sequencing Center for sequencing.  Sequence confirmations were reviewed by Irene 
Bosch and Kris Giaya. 
 
Expression of Recombinant Protein 
 
Cell Transformation  
Samples from an LR miniprep (1 µL) were transformed in 50 µL of competent 
BL21-A1 cell.  Samples were incubated on ice for 10 minutes. After ice incubation, 
samples were heat shocked for 30 seconds at 42°C.  Tubes were immediately transferred 
to ice after heat shock.  Then 250 µL of SOC medium was added to the samples.  
Samples were then incubated for 30 minutes at 37°C while shaking horizontally at 200 
rpm. After incubation, 100 µL of transformation was added to 1 mL of LB-AMP medium 
and incubated overnight at 37°C.  
 After the cultures were grown overnight, 50 µL of culture was plated on pre-
warmed AMP plates and incubated overnight at 37°C. Colonies were picked the 
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following day and cultured overnight in LB-AMP medium at 37°C while shaking 
horizontally at 200 rpm. 
 
Induction 
10 µL of colony culture and 3 mL of LB-AMP medium was mixed and incubated 
at 37°C while shaking horizontally at 200 rpm for about an hour.  Samples were 
incubated until their OD600 was greater than 0.4 nm. The 3 mL of the culture was 
aliquotted into separate 1mL samples for induction. For the IPTG induction, 1 µL of 
IPTG was added to the 1 mL culture. For the arabinose induction, 50 µL of arabinose was 
added to the 1 mL culture.  All samples were mixed well, and then they were incubated 
for about 4-6 hours at 37°C while shaking horizontally at 200 rpm.  The incubation was 
run until the OD600 was greater than 0.7 nm, preferably around 1.5 nm. 
 After induction, samples were centrifuged at high speed for 5 minutes.  The 
supernatant was discarded and the pellet was resuspended in 100 µL of PBS protease 
inhibitor buffer mix (Roche). Cells were then lysed by sonication on ice for 30 seconds. 
20 µL of sample and 20 µL of sample buffer were mixed and boiled at 82°C for 5 
minutes. 
 
Protein Electrophoresis 
Cell lysate proteins were separated by SDS-PAGE gel electrophoresis.  The 
resolving gel consisted of 11.25 mL of 1M Tris pH 8.8, 10 mL of 30% acrylamide, 8.75 
mL of dH2O, 150 µL of fresh 10% APS, and 30 µL of TEMED.  The solution was mixed 
well and poured onto the gel apparatus.  Before the stacking gel was added onto the 
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resolving gel, dH2O was added to the top of the resolving gel to level the resolving gel, it 
was allowed to dry for 10 minutes, and then the water was removed.  The stacking gel 
consisted of 1.25 mL of 1M Tris pH 6.8, 1.25 mL of 30 % acrylamide, 7.41 mL of dH2O, 
75 µL of fresh 10% APS, and 18 µL of TEMED.  The solution was mixed well and 
poured on top of the resolving gel. A comb was placed on the stacking gel in the gel 
apparatus.  The gel was allowed to polymerize for about an hour, then the comb was 
removed once gel solidified. 
 Proteins were run through the gel in Tris/Glycine/SDS Buffer (10x) at 200 volts, 3 
amps, and 200 watts for 2-4 hours.  Gel was run until the bromophenol blue dye was 
approximately 2 cm from the base of the gel. The gel was removed from apparatus and 
stained in Safe Stain solutions for 1 hour at room temperature while shaking.  Destaining 
was performed in dH2O overnight. 
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RESULTS 
 
The purpose of this project was to use genetic engineering to express a variety of 
DEN-2 and WN virus genes for future analysis of the produced proteins against patient 
T-cell responses.  Table 2 below lists the sizes of the known DEN and WN genes used to 
verify RT-PCR DNA amplicon sizes on agarose gels during cloning experiments. 
 
Gene Name Gene Lengths (bp) 
 DEN-2 WN 
C 341 369 
prM 497 278 
E 1484 1503 
NS1 1055 1056 
NS2A 653 693 
NS2B 389 393 
NS3 1844 1857 
NS4A 858 447 
NS4B 336 765 
NS5 2699 2715 
Total Genome 10156 10060 
 
Table 2: DEN-2 and WN Genes.  Table consists of all the DEN and WN genes and their genome 
sizes in base pairs.  This table was used to verify appropriate RT-PCR amplicon band sizes on agarose gels.   
 
Cloning DEN-2 Genes 
DEN-2 entry clone plasmids (C, prM, NS1, NS2A, NS2B, NS4A, NS4B, and 
NS5) were provided to Bosch’s lab by Rothman’s lab at the UMASS Center for 
Infectious Diseases and Vaccine Research.  Entry clone plasmids were used to subclone 
the DEN-2 genes into expression plasmid pDEST 17 by using a LR reaction.  Reactions 
were transformed into Top 10 E. coli cells, then plasmid DNA was prepared from ampr 
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colonies, and screened by PCR (see Figure 9).  Table 3 shows the PCR results of the 
expression plasmid screening.  Positive pDEST 17 expression plasmids were obtained for 
6 of the 8 DEN-2 genes tested (clones were not obtained for NS1 and NS4B).   
 
Figure 9: DEN-2 Gene PCR Screening of LR Reaction pDEST 17 Plasmids.   LR 
reactions were transformed into Top 10 E. coli cells.  Plasmid DNA was extracted from ampr colonies, then 
screened for DEN-2 genes by PCR.  Arrows denote the sizes in bp of positive clones.     
 
Plasmid Vector Cell line OD (ng/µL) Gel Lane Clone result (+/-) 
C1-1 pDEST 17 Top 10 30.6 2 - 
C1-2 pDEST 17 Top 10 65.2 3 - 
C1-3 pDEST 17 Top 10 37.3 4 + 
NS1-1 pDEST 17 Top 10 102.4 5 - 
NS1-2 pDEST 17 Top 10 102.5 6 - 
NS1-3 pDEST 17 Top 10 190.4 7 - 
NS2B-1 pDEST 17 Top 10 78.6 8 + 
NS2B-2 pDEST 17 Top 10 108.1 9 + 
NS2B-3 pDEST 17 Top 10 79.4 10 + 
NS4A-1 pDEST 17 Top 10 101.4 11 + 
341 bp 
389 bp 
858 bp 
2699 bp 
497 bp 653 bp 
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NS4A-2 pDEST 17 Top 10 112 12 - 
NS4A-3 pDEST 17 Top 10 158.9 13 + 
NS4B-1 pDEST 17 Top 10 102.8 14 - 
NS4B-2 pDEST 17 Top 10 96.2 15 - 
NS4B-3 pDEST 17 Top 10 93 16 - 
NS5-1 pDEST 17 Top 10 100 17 + 
NS5-2 pDEST 17 Top 10 134.6 18 + 
NS5-3 pDEST 17 Top 10 128.5 19 + 
Prm-1 pDEST 17 Top 10 32.9 20 + 
Prm-2 pDEST 17 Top 10 64.6 21 + 
Prm-3 pDEST 17 Top 10 41.2 22 - 
NS2A-1 pDEST 17 Top 10 225.7 23 - 
NS2A-2 pDEST 17 Top 10 205.8 24 - 
NS2A-3 pDEST 17 Top 10 178.1 25 + 
 
Table 3:  PCR Screening of the LR Reaction Cloning into Expression 
Plasmid pDEST 17.   LR reactions were transformed into the TOP10 cell strain of 
E.coli, then plasmid DNA was isolated from ampr colonies, and screened by PCR for 
specific DEN-2 genes.  Shown are the sample concentrations and whether cloning was 
successful. 
 
 
The positive DEN-2 expression plasmid samples were sent to the UMASS 
Nucleic Acid Facility (NAF) for sequencing. 
 
Expression of Recombinant DEN-2 Proteins 
Recombinant pDEST 17 plasmids samples were expressed in E. coli  BL21-A1 
cells using IPTG or arabinose induction.  Purified plasmids from an LR recombinant 
reaction were transformed into BL21-A1 cells.  Ampr colonies were grown overnight, 
picked, then cultured overnight again.  Overnight cultures were induced by IPTG or 
arabinose, using the experimental format listed in Table 4.   
 
Sample Induction type OD600 (nm) 
E18 Non-induced 1.578 
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E18 IPTG 0.701 
E18 arabinose 1.549 
E20 Non-induced 1.572 
E20 IPTG 0.714 
E20 Arabinose 1.534 
NS3-15 Non-induced 1.575 
NS3-15 IPTG 0.734 
NS3-15 arabinose 1.541 
 
Table 4:  Induction of DEN-2 Protein Production 
from Recombinant pDEST 17 Plasmids.   Clones E18, 
E20, and NS3-15 were induced until OD600 nm was greater than 0.7. 
 
 
Incubation for induction was for 5 hours, until the OD600 nm were greater than 0.7, 
preferably around 1.5.  After the 5 hour incubation period, the non-induced and arabinose 
samples were above 1.5, so incubation was stopped.  However, IPTG induction samples 
were around 0.7, these samples should have been incubated longer. Cell lysates were 
prepared, then analyzed by SDS-PAGE.  The E18 and E20 clones were positive (data not 
shown) producing protein bands of the expected 50 kDa E protein sizes.  The NS3-15 
clone produced protein bands that were faint but of the expected 60 kDa NS3 size (data 
not shown).  The NS3-15 samples should have been incubated longer to allow a more 
enhanced induction.  
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Cloning WNV Genes 
RT-PCR was performed on WNV RNA to obtain genes NS2A, NS2B, and NS4B 
(Figure 10).  Amplicons were purified from the gel, then used in a BP reaction in an 
attempt to create “entry clone” plasmids.  Plasmid DNA was prepared from ampr 
colonies, then screened by PCR for WN genes.  Unfortunately the screening results were 
negative (data not shown) probably due to a low amplicon DNA yield.   
 
 
Figure 10: WN RT-PCR.   RT-PCR was performed to obtain amplicons for specific WN genes.  
NS2A, NS2B, and NS4B were the targeted proteins.  Two of the 3 produced amplicons of the expected 
sizes (NS2B and NS4B).  The NS2A band was too high, it should have been 693 bp. 
 
  
RT-PCR was redone on WN RNA to obtain the same genes as in Figure 10 plus 
NS5 and NS4A (data not shown), but two attempts failed to obtain the desired amplicons, 
probably because the viral RNA was contaminated. So a WN DNA replicon was 
obtained, it lacked the structural proteins, and was used instead of the RNA.  WN 
393 bp 393 bp 
765 bp 765 bp 
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replicon was used to target the nonstructural proteins NS2A, NS2B, NS4A, NS4B, and 
NS5 (Figure 11).  Correct sized amplicons were obtained for 3 of the 5 genes tested 
(NS2B, NS4A, NS4B), whose DNA was purified. Yields of DNA purification were 
tested by agarose electrophoresis (Figure 12) to confirm purification; visible bands were 
obtained for NS2B and NS4A, but not for NS4B.   It was discovered that there was an 
incorrect primer sequence for NS2A, NS4B, and NS5.  Primers were re-designed and 
ordered for later experiments. 
 
 
Figure 11: PCR of WNV Non-Structural Genes from a WN DNA Replicon.   PCR was 
performed on a WN DNA replicon in an attempt to obtain cDNAs for NS2A, NS2B, NS4A, NS4B, and 
NS5.   Positives were obtained for NS2B, NS4A, and NS4B.  Arrows denote the expected gene sizes in bp.  
There were no visible bands for NS2A and NS5. 
 
393 bp 
447 bp 
765 bp 
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Figure 12: DNA Purification Confirmation Gel.  The yield of DNA from the PCR experiment 
in the previous figure was assayed by agarose electrophoresis.  NS2B and NS4A produced visible bands, 
but NS4B was negative.  
 
 BP and LR recombinant reactions were performed on the NS2B and NS4A 
samples (data not shown) obtaining successful positives for each, but the SDS-PAGE 
results were negative. 
 PCR of the WN replicon was redone for genes NS2A, NS2B, NS4A, NS4B, and 
NS5.  The PCR results were all positive (data not shown), the bands were extracted, DNA 
was purified, and the BP and LR recombinant reactions were performed.  All samples 
were transformed in TOP10 cells and plasmids were screened by PCR.  Figure 13 shows 
the successful cloning of NS5 into expression plasmid pDEST 17, while Figure 14 shows 
the successful cloning of NS4A into both pDONOR 221, and expression plasmid pDEST 
17.    
393 bp 
447 bp 
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Figure 13: Cloning of WN NS5 into Expression Plasmid pDEST 17 by Using the LR 
Reaction.   The NS5 LR reaction was transformed into TOP10 cells, selected with Ampicillin, and 
plasmid DNA purified. Plasmids were screened by PCR.  Lane 4 was the only positive sample. 
 
 
 
Figure 14: Plasmid Screening for WN NS4A.  Lanes 2-4 were NS4A entry clones in plasmid 
pDONOR 221, from a BP recombinant reaction (TOP10 cells, selected with Kanamycin, and plasmids 
isolated by minipreps). All 3 lanes were positive.  Lanes 5-10 represent the subcloning of NS4A into 
expression plasmid pDEST 17 using the LR recombinant reaction (TOP10 cells, selected with Ampicillin, 
and plasmid DNA purified by minipreps). All lanes contained positives of the correct size, 447 bp. 
 
 
Unfortunately no expression test of the successfully cloned NS5 and NS4A 
pDEST 17 clones could be completed since Bosch’s lab was not allowed to work with 
WN due to NIH contract issues. 
2714 bp 
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DISCUSSION 
 
The data shows that 6 DEN-2 genes, C, prM, NS2A, NS2B, NS4A, and NS5, 
were amplified and cloned successfully into an expression vector.  Figure 9 and Table 3 
clearly demonstrate the PCR screening of the cloned DEN-2 genes into expression 
plasmids pDEST 17.  Two DEN-2 genes, NS3 and E, were successfully expressed in E. 
coli cells.  Data also shows that WN genes, NS4A (Figure 14) and NS5 (Figure 13), were 
amplified and cloned successfully.   
The project objective was to finish the cloning and expression of several 
remaining viral proteins of DEN-2 and WN virus in bacterial and mammalian cells.  
Unfortunately, the objective wasn’t fully accomplished.  6 out of the 10 DEN-2 viral 
proteins (C, prM, NS2A, NS2B, NS4A, and NS5) were successfully cloned.  Two other 
viral genes (E and NS3) that were previously cloned were successfully expressed in 
bacterial cells.  2 (NS4A and NS5) out of the 5 targeted WN viral proteins (NS2A, NS2B, 
NS4A, NS4B, and NS5) were successfully cloned.  Unfortunately, expression in bacterial 
cells wasn’t performed due to NIH contract issues. Due to lack of time and NIH contract 
issues, expression in mammalian cells was not feasible for any of the cloned viral 
proteins.  
Bosch’s lab continues to study DEN and WN to further understand the viruses. 
They will need to complete the cloning and expression of all remaining DEN-2 and WN 
viral proteins in bacterial and mammalian cells.  They will also need to clone and express 
DEN-1, DEN-3, and DEN-4 viral proteins. All cloned and expressed genes will be used 
to test T-cell reactivity from infected patients, or to create antibodies to facilitate further 
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analysis of protein function. The next step of the research is to investigate the role of the 
viral proteins in inflammation by measuring the levels of cytokines secreted by cells 
transfected with the expression plasmids. 
A more complete understanding of the viral proteins will bring a vast knowledge 
to the pathogenesis of DEN and WN.  Hopefully all this newfound knowledge can be 
used to develop a vaccine for DEN and WN; and to develop a more rapid, sensitive, and 
specific diagnostic test.  
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APPENDIX 1- West Nile Genome Sequence  
 
West Nile virus NY-99 flamingo (AF 196835) 
 
 
1 agtagttcgc ctgtgtgagc tgacaaactt agtagtgttt gtgaggatta acaacaatta 
61 acacagtgcg agctgtttct tagcacgaag atctcgatgt ctaagaaacc aggagggccc 
121 ggcaagagcc gggctgtcaa tatgctaaaa cgcggaatgc cccgcgtgtt gtccttgatt 
181 ggactgaaga gggctatgtt gagcctgatc gacggcaagg ggccaatacg atttgtgttg 
241 gctctcttgg cgttcttcag gttcacagca attgctccga cccgagcagt gctggatcga 
301 tggagaggtg tgaacaaaca aacagcgatg aaacaccttc tgagttttaa gaaggaacta 
361 gggaccttga ccagtgctat caatcggcgg agctcaaaac aaaagaaaag aggaggaaag 
421 accggaattg cagtcatgat tggcctgatc gccagcgtag gagcagttac cctctctaac 
481 ttccaaggga aggtgatgat gacggtaaat gctactgacg tcacagatgt catcacgatt 
541 ccaacagctg ctggaaagaa cctatgcatt gtcagagcaa tggatgtggg atacatgtgc 
601 gatgatacta tcacttatga atgcccagtg ctgtcggctg gtaatgatcc agaagacatc 
661 gactgttggt gcacaaagtc agcagtctac gtcaggtatg gaagatgcac caagacacgc 
721 cactcaagac gcagtcggag gtcactgaca gtgcagacac acggagaaag cactctagcg 
781 aacaagaagg gggcttggat ggacagcacc aaggccacaa ggtatttggt aaaaacagaa 
841 tcatggatct tgaggaaccc tggatatgcc ctggtggcag ccgtcattgg ttggatgctt 
901 gggagcaaca ccatgcagag agttgtgttt gtcgtgctat tgcttttggt ggccccagct 
961 tacagcttca actgccttgg aatgagcaac agagacttct tggaaggagt gtctggagca 
1021 acatgggtgg atttggttct cgaaggcgac agctgcgtga ctatcatgtc taaggacaag 
1081 cctaccatcg atgtgaagat gatgaatatg gaggcggcca acctggcaga ggtccgcagt 
1141 tattgctatt tggctaccgt cagcgatctc tccaccaaag ctgcgtgccc gaccatggga 
1201 gaagctcaca atgacaaacg tgctgaccca gcttttgtgt gcagacaagg agtggtggac 
1261 aggggctggg gcaacggctg cggactattt ggcaaaggaa gcattgacac atgcgccaaa 
1321 tttgcctgct ctaccaaggc aataggaaga accatcttga aagagaatat caagtacgaa 
1381 gtggccattt ttgtccatgg accaactact gtggagtcgc acggaaacta ctccacacag 
1441 gttggagcca ctcaggcagg gagattcagc atcactcctg cggcgccttc atacacacta 
1501 aagcttggag aatatggaga ggtgacagtg gactgtgaac cacggtcagg gattgacacc 
1561 aatgcatact acgtgatgac tgttggaaca aagacgttct tggtccatcg tgagtggttc 
1621 atggacctca acctcccttg gagcagtgct ggaagtactg tgtggaggaa cagagagacg 
1681 ttaatggagt ttgaggaacc acacgccacg aagcagtctg tgatagcatt gggctcacaa 
1741 gagggagctc tgcatcaagc tttggctgga gccattcctg tggaattttc aagcaacact 
1801 gtcaagttga cgtcgggtca tttgaagtgt agagtgaaga tggaaaaatt gcagttgaag 
1861 ggaacaacct atggcgtctg ttcaaaggct ttcaagtttc ttgggactcc cgcagacaca 
1921 ggtcacggca ctgtggtgtt ggaattgcag tacactggca cggatggacc ttgcaaagtt 
1981 cctatctcgt cagtggcttc attgaacgac ctaacgccag tgggcagatt ggtcactgtc 
2041 aacccttttg tttcagtggc cacggccaac gctaaggtcc tgattgaatt ggaaccaccc 
2101 tttggagact catacatagt ggtgggcaga ggagaacaac agatcaatca ccattggcac 
2161 aagtctggaa gcagcattgg caaagccttt acaaccaccc tcaaaggagc gcagagacta 
2221 gccgctctag gagacacagc ttgggacttt ggatcagttg gaggggtgtt cacctcagtt 
2281 gggaaggctg tccatcaagt gttcggagga gcattccgct cactgttcgg aggcatgtcc 
2341 tggataacgc aaggattgct gggggctctc ctgttgtgga tgggcatcaa tgctcgtgat 
2401 aggtccatag ctctcacgtt tctcgcagtt ggaggagttc tgctcttcct ctccgtgaac 
2461 gtgcacgctg acactgggtg tgccatagac atcagccggc aagagctgag atgtggaagt 
2521 ggagtgttca tacacaatga tgtggaggct tggatggacc ggtacaagta ttaccctgaa 
2581 acgccacaag gcctagccaa gatcattcag aaagctcata aggaaggagt gtgcggtcta 
2641 cgatcagttt ccagactgga gcatcaaatg tgggaagcag tgaaggacga gctgaacact 
2701 cttttgaagg agaatggtgt ggaccttagt gtcgtggttg agaaacagga gggaatgtac 
2761 aagtcagcac ctaaacgcct caccgccacc acggaaaaat tggaaattgg ctggaaggcc 
2821 tggggaaaga gtattttatt tgcaccagaa ctcgccaaca acacctttgt ggttgatggt 
2881 ccggagacca aggaatgtcc gactcagaat cgcgcttgga atagcttaga agtggaggat 
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2941 tttggatttg gtctcaccag cactcggatg ttcctgaagg tcagagagag caacacaact 
3001 gaatgtgact cgaagatcat tggaacggct gtcaagaaca acttggcgat ccacagtgac 
3061 ctgtcctatt ggattgaaag caggctcaat gatacgtgga agcttgaaag ggcagttctg 
3121 ggtgaagtca aatcatgtac gtggcctgag acgcatacct tgtggggcga tggaatcctt 
3181 gagagtgact tgataatacc agtcacactg gcgggaccac gaagcaatca caatcggaga 
3241 cctgggtaca agacacaaaa ccagggccca tgggacgaag gccgggtaga gattgacttc 
3301 gattactgcc caggaactac ggtcaccctg agtgagagct gcggacaccg tggacctgcc 
3361 actcgcacca ccacagagag cggaaagttg ataacagatt ggtgctgcag gagctgcacc 
3421 ttaccaccac tgcgctacca aactgacagc ggctgttggt atggtatgga gatcagacca 
3481 cagagacatg atgaaaagac cctcgtgcag tcacaagtga atgcttataa tgctgatatg 
3541 attgaccctt ttcagttggg ccttctggtc gtgttcttgg ccacccagga ggtccttcgc 
3601 aagaggtgga cagccaagat cagcatgcca gctatactga ttgctctgct agtcctggtg 
3661 tttgggggca ttacttacac tgatgtgtta cgctatgtca tcttggtggg ggcagctttc 
3721 gcagaatcta attcgggagg agacgtggta cacttggcgc tcatggcgac cttcaagata 
3781 caaccagtgt ttatggtggc atcgtttctc aaagcgagat ggaccaacca ggagaacatt 
3841 ttgttgatgt tggcggctgt tttctttcaa atggcttatc acgatgcccg ccaaattctg 
3901 ctctgggaga tccctgatgt gttgaattca ctggcggtag cttggatgat actgagagcc 
3961 ataacattca caacgacatc aaacgtggtt gttccgctgc tagccctgct aacacccggg 
4021 ctgagatgct tgaatctgga tgtgtacagg atactgctgt tgatggtcgg aataggcagc 
4081 ttgatcaggg agaagaggag tgcagctgca aaaaagaaag gagcaagtct gctatgcttg 
4141 gctctagcct caacaggact tttcaacccc atgatccttg ctgctggact gattgcatgt 
4201 gatcccaacc gtaaacgcgg atggcccgca actgaagtga tgacagctgt cggcctaatg 
4261 tttgccatcg tcggagggct ggcagagctt gacattgact ccatggccat tccaatgact 
4321 atcgcggggc tcatgtttgc tgctttcgtg atttctggga aatcaacaga tatgtggatt 
4381 gagagaacgg cggacatttc ctgggaaagt gatgcagaaa ttacaggctc gagcgaaaga 
4441 gttgatgtgc ggcttgatga tgatggaaac ttccagctca tgaatgatcc aggagcacct 
4501 tggaagatat ggatgctcag aatggtctgt ctcgcgatta gtgcgtacac cccctgggca 
4561 atcttgccct cagtagttgg attttggata actctccaat acacaaagag aggaggcgtg 
4621 ttgtgggaca ctccctcacc aaaggagtac aaaaaggggg acacgaccac cggcgtctac 
4681 aggatcatga ctcgtgggct gctcggcagt tatcaagcag gagcgggcgt gatggttgaa 
4741 ggtgttttcc acaccctttg gcatacaaca aaaggagccg ctttgatgag cggagagggc 
4801 cgcctggacc catactgggg cagtgtcaag gaggatcgac tttgttacgg aggaccctgg 
4861 aaattgcagc acaagtggaa cgggcaggat gaggtgcaga tgattgtggt ggaacctggc 
4921 aagaacgtta agaacgtcca gacgaaacca ggggtgttca aaacacctga aggagaaatc 
4981 ggggccgtga ctttggactt ccccactgga acatcaggct caccaatagt ggacaaaaac 
5041 ggtgatgtga ttgggcttta tggcaatgga gtcataatgc ccaacggctc atacataagc 
5101 gcgatagtgc agggtgaaag gatggatgag ccaatcccag ccggattcga acctgagatg 
5161 ctgaggaaaa aacagatcac tgtactggat ctccatcccg gcgccggtaa aacaaggagg 
5221 attctgccac agatcatcaa agaggccata aacagaagac tgagaacagc cgtgctagca 
5281 ccaaccaggg ttgtggctgc tgagatggct gaagcactga gaggactgcc catccggtac 
5341 cagacatccg cagtgcccag agaacataat ggaaatgaga ttgttgatgt catgtgtcat 
5401 gctaccctca cccacaggct gatgtctcct cacagggtgc cgaactacaa cctgttcgtg 
5461 atggatgagg ctcatttcac cgacccagct agcattgcag caagaggtta catttccaca 
5521 aaggtcgagc taggggaggc ggcggcaata ttcatgacag ccaccccacc aggcacttca 
5581 gatccattcc cagagtccaa ttcaccaatt tccgacttac agactgagat cccggatcga 
5641 gcttggaact ctggatacga atggatcaca gaatacaccg ggaagacggt ttggtttgtg 
5701 cctagtgtca agatggggaa tgagattgcc ctttgcctac aacgtgctgg aaagaaagta 
5761 gtccaattga acagaaagtc gtacgagacg gagtacccaa aatgtaagaa cgatgattgg 
5821 gactttgtta tcacaacaga catatctgaa atgggggcta acttcaaggc gagcagggtg 
5881 attgacagcc ggaagagtgt gaaaccaacc atcataacag aaggagaagg gagagtgatc 
5941 ctgggagaac catctgcagt gacagcagct agtgccgccc agagacgtgg acgtatcggt 
6001 agaaatccgt cgcaagttgg tgatgagtac tgttatgggg ggcacacgaa tgaagacgac 
6061 tcgaacttcg cccattggac tgaggcacga atcatgctgg acaacatcaa catgccaaac 
6121 ggactgatcg ctcaattcta ccaaccagag cgtgagaagg tatataccat ggatggggaa 
6181 taccggctca gaggagaaga gagaaaaaac tttctggaac tgttgaggac tgcagatctg 
6241 ccagtttggc tggcttacaa ggttgcagcg gctggagtgt cataccacga ccggaggtgg 
6301 tgctttgatg gtcctaggac aaacacaatt ttagaagaca acaacgaagt ggaagtcatc 
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6361 acgaagcttg gtgaaaggaa gattctgagg ccgcgctgga ttgacgccag ggtgtactcg 
6421 gatcaccagg cactaaaggc gttcaaggac ttcgcctcgg gaaaacgttc tcagataggg 
6481 ctcattgagg ttctgggaaa gatgcctgag cacttcatgg ggaagacatg ggaagcactt 
6541 gacaccatgt acgttgtggc cactgcagag aaaggaggaa gagctcacag aatggccctg 
6601 gaggaactgc cagatgctct tcagacaatt gccttgattg ccttattgag tgtgatgacc 
6661 atgggagtat tcttcctcct catgcagcgg aagggcattg gaaagatagg tttgggaggc 
6721 gctgtcttgg gagtcgcgac ctttttctgt tggatggctg aagttccagg aacgaagatc 
6781 gccggaatgt tgctgctctc ccttctcttg atgattgtgc taattcctga gccagagaag 
6841 caacgttcgc agacagacaa ccagctagcc gtgttcctga tttgtgtcat gacccttgtg 
6901 agcgcagtgg cagccaacga gatgggttgg ctagataaga ccaagagtga cataagcagt 
6961 ttgtttgggc aaagaattga ggtcaaggag aatttcagca tgggagagtt tcttttggac 
7021 ttgaggccgg caacagcctg gtcactgtac gctgtgacaa cagcggtcct cactccactg 
7081 ctaaagcatt tgatcacgtc agattacatc aacacctcat tgacctcaat aaacgttcag 
7141 gcaagtgcac tattcacact cgcgcgaggc ttccccttcg tcgatgttgg agtgtcggct 
7201 ctcctgctag cagccggatg ctggggacaa gtcaccctca ccgttacggt aacagcggca 
7261 acactccttt tttgccacta tgcctacatg gttcccggtt ggcaagctga ggcaatgcgc 
7321 tcagcccagc ggcggacagc ggccggaatc atgaagaacg ctgtagtgga tggcatcgtg 
7381 gccacggacg tcccagaatt agagcgcacc acacccatca tgcagaagaa agttggacag 
7441 atcatgctga tcttggtgtc tctagctgca gtagtagtga acccgtctgt gaagacagta 
7501 cgagaagccg gaattttgat cacggccgca gcggtgacgc tttgggagaa tggagcaagc 
7561 tctgtttgga acgcaacaac tgccatcgga ctctgccaca tcatgcgtgg gggttggttg 
7621 tcatgtctat ccataacatg gacactcata aagaacatgg aaaaaccagg actaaaaaga 
7681 ggtggggcaa aaggacgcac cttgggagag gtttggaaag aaagactcaa ccagatgaca 
7741 aaagaagagt tcactaggta ccgcaaagag gccatcatcg aagtcgatcg ctcagcggca 
7801 aaacacgcca ggaaagaagg caatgtcact ggagggcatc cagtctctag gggcacagca 
7861 aaactgagat ggctggtcga acggaggttt ctcgaaccgg tcggaaaagt gattgacctt 
7921 ggatgtggaa gaggcggttg gtgttactat atggcaaccc aaaaaagagt ccaagaagtc 
7981 agagggtaca caaagggcgg tcccggacat gaagagcccc aactagtgca aagttatgga 
8041 tggaacattg tcaccatgaa gagtggagtg gatgtgttct acagaccttc tgagtgttgt 
8101 gacaccctcc tttgtgacat cggagagtcc tcgtcaagtg ctgaggttga agagcatagg 
8161 acgattcggg tccttgaaat ggttgaggac tggctgcacc gagggccaag ggaattttgc 
8221 gtgaaggtgc tctgccccta catgccgaaa gtcatagaga agatggagct gctccaacgc 
8281 cggtatgggg ggggactggt cagaaaccca ctctcacgga attccacgca cgagatgtat 
8341 tgggtgagtc gagcttcagg caatgtggta cattcagtga atatgaccag ccaggtgctc 
8401 ctaggaagaa tggaaaaaag gacctggaag ggaccccaat acgaggaaga tgtaaacttg 
8461 ggaagtggaa ccagggcggt gggaaaaccc ctgctcaact cagacaccag taaaatcaag 
8521 aacaggattg aacgactcag gcgtgagtac agttcgacgt ggcaccacga tgagaaccac 
8581 ccatatagaa cctggaacta tcacggcagt tatgatgtga agcccacagg ctccgccagt 
8641 tcgctggtca atggagtggt caggctcctc tcaaaaccat gggacaccat cacgaatgtt 
8701 accaccatgg ccatgactga cactactccc ttcgggcagc agcgagtgtt caaagagaag 
8761 gtggacacga aagctcctga accgccagaa ggagtgaagt acgtgctcaa tgagaccacc 
8821 aactggttgt gggcgttttt ggccagagaa aaacgtccca gaatgtgctc tcgagaggaa 
8881 ttcataagaa aggtcaacag caatgcagct ttgggtgcca tgtttgaaga gcagaatcaa 
8941 tggaggagcg ccagagaagc agttgaagat ccaaaatttt gggagatggt ggatgaggag 
9001 cgcgaggcac atctgcgggg ggaatgtcac acttgcattt acaacatgat gggaaagaga 
9061 gagaaaaaac ccggagagtt cggaaaggcc aagggaagca gagccatttg gttcatgtgg 
9121 ctcggagctc gctttctgga gttcgaggct ctgggttttc tcaatgaaga ccactggctt 
9181 ggaagaaaga actcaggagg aggtgtcgag ggcttgggcc tccaaaaact gggttacatc 
9241 ctgcgtgaag ttggcacccg gcctgggggc aagatctatg ctgatgacac agctggctgg 
9301 gacacccgca tcacgagagc tgacttggaa aatgaagcta aggtgcttga gctgcttgat 
9361 ggggaacatc ggcgtcttgc cagggccatc attgagctca cctatcgtca caaagttgtg 
9421 aaagtgatgc gcccggctgc tgatggaaga accgtcatgg atgttatctc cagagaagat 
9481 cagaggggga gtggacaagt tgtcacctac gccctaaaca ctttcaccaa cctggccgtc 
9541 cagctggtga ggatgatgga aggggaagga gtgattggcc cagatgatgt ggagaaactc 
9601 acaaaaggga aaggacccaa agtcaggacc tggctgtttg agaatgggga agaaagactc 
9661 agccgcatgg ctgtcagtgg agatgactgt gtggtaaagc ccctggacga tcgctttgcc 
9721 acctcgctcc acttcctcaa tgctatgtca aaggttcgca aagacatcca agagtggaaa 
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9781 ccgtcaactg gatggtatga ttggcagcag gttccatttt gctcaaacca tttcactgaa 
9841 ttgatcatga aagatggaag aacactggtg gttccatgcc gaggacagga tgaattggta 
9901 ggcagagctc gcatatctcc aggggccgga tggaacgtcc gcgacactgc ttgtctggct 
9961 aagtcttatg cccagatgtg gctgcttctg tacttccaca gaagagacct gcggctcatg 
10021 gccaacgcca tttgctccgc tgtccctgtg aattgggtcc ctaccggaag aaccacgtgg 
10081 tccatccatg caggaggaga gtggatgaca acagaggaca tgttggaggt ctggaaccgt 
10141 gtttggatag aggagaatga atggatggaa gacaaaaccc cagtggagaa atggagtgac 
10201 gtcccatatt caggaaaacg agaggacatc tggtgtggca gcctgattgg cacaagagcc 
10261 cgagccacgt gggcagaaaa catccaggtg gctatcaacc aagtcagagc aatcatcgga 
10321 gatgagaagt atgtggatta catgagttca ctaaagagat atgaagacac aactttggtt 
10381 gaggacacag tactgtagat atttaatcaa ttgtaaatag acaatataag tatgcataaa 
10441 agtgtagttt tatagtagta tttagtggtg ttagtgtaaa tagttaagaa aattttgagg 
10501 agaaagtcag gccgggaagt tcccgccacc ggaagttgag tagacggtgc tgcctgcgac 
10561 tcaaccccag gaggactggg tgaacaaagc cgcgaagtga tccatgtaag ccctcagaac 
10621 cgtctcggaa ggaggacccc acatgttgta acttcaaagc ccaatgtcag accacgctac 
10681 ggcgtgctac tctgcggaga gtgcagtctg cgatagtgcc ccaggaggac tgggttaaca 
10741 aaggcaaacc aacgccccac gcggccctag ccccggtaat ggtgttaacc agggcgaaag 
10801 gactagaggt tagaggagac cccgcggttt aaagtgcacg gcccagcctg actgaagctg 
10861 taggtcaggg gaaggactag aggttagtgg agaccccgtg ccacaaaaca ccacaacaaa 
10921 acagcatatt gacacctggg atagactagg agatcttctg ctctgcacaa ccagccacac 
10981 ggcacagtgc gccgacaatg gtggctggtg gtgcgagaac acaggatct 
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APPENDIX 2- Dengue Virus Genome Sequence 
 
Dengue virus type 2 New Guinea-C (M29095) 
 
 
1 nnnnnnnagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaacgta 
61 gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg aaaaaaggcg 
121 agaaatacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtacaacag 
181 ctgacaaaga gattctcact tggaatgctg cagggacgag gaccattaaa actgttcatg 
241 gccctggtgg cgttccttcg tttcctaaca atcccaccaa cagcagggat actgaagaga 
301 tggggaacaa ttaaaaaatc aaaagccatt aatgttttga gagggttcag gaaagagatt 
361 ggaaggatgc tgaacatctt gaacaggaga cgcagaactg caggcatgat cattatgctg 
421 attccaacag tgatggcgtt ccatttaacc acacgtaacg gagaaccaca catgatcgtc 
481 agtagacaag agaaagggaa aagtcttctg tttaaaacag aggatggtgt gaacatgtgt 
541 accctcatgg ccatggacct tggtgaattg tgtgaagata caatcacgta caagtgtcct 
601 tttctcaagc agaatgaacc agaagacata gattgttggt gcaactctac gtccacatgg 
661 gtaacttatg ggacgtgtac caccacagga gaacacagaa gagaaaaaag atcagtggca 
721 ctcgttccac atgtgggaat gggactggag acacgaactg aaacatggat gtcatcagaa 
781 ggggcctgga aacatgccca gagaattgaa acttggatct tgagacatcc aggctttacc 
841 ataatggcag caatcctggc atacaccata ggaacgacac atttccaaag agccctgatt 
901 ttcatcttac tgacagctgt cgctccttca atgacaatgc gttgcatagg aatatcaaat 
961 agagactttg tagaaggggt ttcaggagga agctgggttg acatagtctt agaacatgga 
1021 agctgtgtga cgacgatggc aaaaaacaaa ccaacattgg attttgaact gatagaaaca 
1081 gaagccaaac aacctgccac tctaaggaag tactgtatag aggcaaagct gaccaacaca 
1141 acaacagatt ctcgctgccc aacacaagga gaacccagcc taaatgaaga gcaggacaaa 
1201 aggttcgtct gcaaacactc catggtggac agaggatggg gaaatggatg tggactattt 
1261 ggaaaaggag gcattgtgac ctgtgctatg ttcacatgca aaaagaacat gaaaggaaaa 
1321 gtcgtgcaac cagaaaactt ggaatacacc attgtgataa cacctcactc aggggaagag 
1381 catgcagtcg gaaatgacac aggaaaacat ggcaaggaaa tcaaaataac accacagagt 
1441 tccatcacag aagcagagtt gacaggctat ggcactgtca cgatggagtg ctctccgaga 
1501 acgggcctcg acttcaatga gatggtgttg ctgcaaatgg aaaataaagc ttggctggtg 
1561 cacaggcaat ggttcctaga cctgccgttg ccatggctgc ccggagcgga cacacaagga 
1621 tcaaattgga tacagaaaga gacattggtc actttcaaaa atccccatgc gaagaaacag 
1681 gatgttgttg ttttgggatc ccaagaaggg gccatgcaca cagcactcac aggggccaca 
1741 gaaatccaga tgtcatcagg aaacttactg ttcacaggac atctcaagtg caggctgagg 
1801 atggacaaac tacagctcaa aggaatgtca tactctatgt gcacaggaaa gtttaaagtt 
1861 gtgaaggaaa tagcagaaac acaacatgga acaatagtta tcagagtaca atatgaaggg 
1921 gacggttctc catgtaagat cccttttgag ataatggatt tggaaaaaag acatgtttta 
1981 ggtcgcctga ttacagtcaa cccaatcgta acagaaaaag atagcccagt caacatagaa 
2041 gcagaacctc cattcggaga cagctacatc atcataggag tagagccggg acaattgaag 
2101 ctcaactggt ttaagaaagg aagttctatc ggccaaatga ttgagacaac aatgagggga 
2161 gcgaagagaa tggccatttt aggtgacaca gcttgggatt ttggatccct gggaggagtg 
2221 tttacatcta taggaaaggc tctccaccaa gttttcggag caatctatgg ggctgccttc 
2281 agtggggtct catggattat gaaaatcctc ataggagtca ttatcacatg gataggaatg 
2341 aattcacgca gcacctcact gtctgtgtca ctagtattgg tgggagtcgt gacgctgtat 
2401 ttgggagtta tggtgcaggc cgatagtggt tgcgttgtga gctggaaaaa caaagaactg 
2461 aagtgtggca gtgggatttt catcacagac aacgtgcaca catggacaga acaatacaag 
2521 ttccaaccag aatccccttc aaaactagct tcagctatcc agaaagctca tgaagagggc 
2581 atttgtggaa tccgctcagt aacaagactg gaaaatctga tgtggaaaca aataacacca 
2641 gaattgaatc acattctatc agaaaatgag gtgaagttga ctattatgac aggagacatc 
2701 aaaggaatca tgcaggcagg aaaacgatct ctgcagcccc agcccactga gctgaagtat 
2761 tcatggaaaa catggggcaa agcgaaaatg ctctctacag agtctcataa ccagaccttt 
2821 ctcattgatg gccccgaaac agcagaatgc cccaacacaa acagagcttg gaattcgctg 
2881 gaagttgaag actatggctt tggagtattc accaccaata tatggctaaa gttgagagaa 
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2941 aagcaggatg tattctgcga ctcaaaactc atgtcagcgg ccataaaaga caacagagcc 
3001 gtccatgccg atatgggtta ttggatagaa agtgcactca atgacacatg gaagatagag 
3061 aaagcctctt tcatcgaagt taaaagctgc cactggccaa agtcacacac cctctggagt 
3121 aatggagtgt tagaaagtga gatgataatt ccaaagaatt tcgctggacc agtgtcacaa 
3181 cacaactaca gaccaggcta ccatacacaa acagcaggac catggcatct aggtaagctt 
3241 gagatggact ttgatttctg cgaaggaacc acagtggtgg tgactgagga ctgtggaaat 
3301 agaggaccct ctttaagaac aactactgcc tctggaaaac tcataacaga atggtgctgc 
3361 cgatcttgca cattaccacc gctaagatac agaggtgagg acggatgctg gtacgggatg 
3421 gaaatcagac cattgaaaga gaaagaagag aatttggtca actccttggt cacagccgga 
3481 catgggcaga ttgacaactt ttcactagga gtcttgggaa tggcattgtt cctggaagaa 
3541 atgctcagga cccgagtagg aacgaaacat gcaatactac tagttgcagt ttcttttgtg 
3601 acattgatca cagggaacat gtcctttaga gacctgggaa gagtgatggt tatggtgggc 
3661 gctactatga cggatgacat aggtatgggc gtgacttatc ttgccctact agcagccttc 
3721 aaagtcagac caacttttgc agctggacta ctcttgagaa agttgacctc caaggaattg 
3781 atgatgacta ccataggaat cgtactcctc tcccagagca ccataccaga gaccattctt 
3841 gaactgactg atgcgttagc cttgggcatg atggttctta aaatggtgag aaaaatggaa 
3901 aagtatcaat tggcagtgac tatcatggct atcttgtgcg tcccaaatgc agtgatatta 
3961 caaaacgcat ggaaagtgag ttgcacaata ttggcagtgg tgtccgtttc cccactgttc 
4021 ttaacatcct cacagcagaa agcggattgg ataccattag cattgacgat caagggtctc 
4081 aatccaacag ctatttttct aacaaccctt tcaagaacca acaagaaaag gagctggcca 
4141 ctaaatgagg ctatcatggc agtcgggatg gtgagcattt tggccagttc actcctaaag 
4201 aatgacattc ccatgacagg accattagtg gctggagggc tcctcactgt gtgctacgtg 
4261 ctcactggac gatcggccga tttggaactg gagagagccg ccgatgtcaa atgggaagat 
4321 caggcagaga tatcaggaag cagtccaatc ctgtcaataa caatatcaga agatggtagc 
4381 atgtcgataa aaaacgaaga ggaagaacaa acactgacca tactcatcag aacaggattg 
4441 ctggtgatct caggactttt tcctgtatca ataccaatca cggcagcagc atggtacctg 
4501 tgggaagtga agaaacaacg ggctggagta ttgtgggatg tcccttcacc cccacccgtg 
4561 ggaaaggctg aactggaaga tggagcctat agaatcaagc aaaaagggat tcttggatat 
4621 tcccagatcg gagccggagt ttacaaagaa ggaacattcc atacaatgtg gcatgtcaca 
4681 cgcggcgctg ttctaatgca taaaggaaag aggattgaac catcatgggc ggacgttaag 
4741 aaagacctaa tatcatatgg aggaggctgg aagctagaag gagaatggaa ggaaggagaa 
4801 gaagtccagg tcttggcatt ggagcctgga aaaaatccaa gagccgtcca aacaaaacct 
4861 ggtcttttca aaaccaacgc cggaaccata ggtgccgtat ctctggactt ttctcctgga 
4921 acctcaggat cgccaatcat cgacaaaaaa ggaaaagttg tgggtcttta tggtaatggt 
4981 gttgttacaa ggagtggagc atatgtgagt gctatagccc agactgaaaa aagtattgaa 
5041 gacaatccag agatcgaaga tgacattttt cgaaagagaa aattgaccat catggacctc 
5101 cacccaggag cgggaaagac gaagagatac cttccggcca tagtcagaga ggctataaaa 
5161 cggggcctga ggacattaat cctggccccc actagagtcg tggcagctga aatggaggaa 
5221 gccctaagag gacttccaat aagataccaa accccagcca tcagagctga gcacaccggg 
5281 cgggagattg tggacctaat gtgtcatgcc acattcacta tgaggctgct atcaccagtt 
5341 agagtgccaa attacaacct gatcatcatg gacgaagccc atttcacaga cccagcaagt 
5401 atagcggcta gaggatacat ctcaactcga gtagagatgg gtgaggcagc tgggattttc 
5461 atgacagcca ctcctccggg aagcagagac ccattccctc agagcaatgc accaatcatg 
5521 gatgaagaaa gagaaatccc tgaacgttcg tggagttctg gacatgagtg ggtcacggat 
5581 tttaaaggga agactgtttg gttcgttcca agtataaaag caggaaatga tatagcagct 
5641 tgcctgagaa aaaatggaaa gaaagtgata caactcagta ggaagacctt tgattctgag 
5701 tatgtcaaga ctagaaccaa tgattgggac ttcgtggtca caactgacat ttcagaaatg 
5761 ggtgccaact tcaaggctga gagggttata gaccccagac gctgcatgaa accagttata 
5821 ctaacagatg gtgaagagcg ggtgatcctg gcaggaccta tgccagtgac ccactctagt 
5881 gcagcacaaa gaagagggag aataggaaga aatccaaaaa atgaaaatga ccagtacata 
5941 tacatggggg aacctctgga aaatgatgaa gactgtgcac actggaaaga agctaaaatg 
6001 ctcctagata acatcaacac acctgaagga atcattccta gcatgttcga accagagcgt 
6061 gaaaaggtgg atgccattga tggtgaatac cgcttgagag gagaagcaag gaaaaccttt 
6121 gtggacctaa tgagaagagg agacctacca gtctggttgg cctacagagt ggcagccgaa 
6181 ggcatcaact acgcagacag aaggtggtgt tttgatggaa ttaagaacaa ccaaatcttg 
6241 gaagaaaatg tggaggtgga aatctggaca aaagaagggg aaaggaagaa attaaaaccc 
6301 agatggttgg atgccaagat ctactctgac ccactggcgc taaaggaatt caaggagttt 
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6361 gcagctggaa gaaagtccct gaccctgaac ctaatcacag aaatgggtag gcttccaact 
6421 ttcatgactc agaaggcaag agacgcactg gacaacttag cagtgctgca cacggctgaa 
6481 gcaggaggaa gggcgtacaa tcatgctctc agtgaactgc cggagaccct ggagacattg 
6541 cttttactga cacttctggc tacagtcaca ggaggaatct ttttattctt gatgagcgga 
6601 aggggtatag ggaagatgac cctgggaatg tgctgcataa tcacggctag tattctccta 
6661 tggtacgcac aaatacagcc acactggata gcagcttcaa taatactgga gttttttctc 
6721 atagttttgc ttattccaga accagaaaag cagagaacac cccaagataa ccaattgacc 
6781 tacgttgtca tagccatcct cacagtggtg gccgcaacca tggcaaacga gatgggtttc 
6841 ctggaaaaaa cgaagaaaga tctcggattg ggaagcatta caacccagca acccgagagc 
6901 aacatcctgg acatagatct acgtcccgca tcagcatgga cgctgtatgc tgtggccaca 
6961 acatttgtca caccaatgtt gagacacagc attgaaaatt cctcagtgaa cgtgtcccta 
7021 acagctattg ccaaccaagc cacagtgtta atgggtcttg ggaaaggatg gccattgtca 
7081 aagatggaca tcggagttcc ccttctcgcc attggatgct actcacaagt caaccccata 
7141 actctcacag cagctctttt cttactggta gcacattatg ccatcatagg gccaggactc 
7201 caagcaaaag caaccagaga agctcagaaa agagcagcag cgggcatcat gaaaaaccca 
7261 actgtcgatg gaataacagt gattgaccta gatccaatac cctatgatcc aaagtttgaa 
7321 aagcagttgg gacaagtaat gctcctagtc ctctgcgtga ctcaagtgtt gatgatgagg 
7381 actacatggg ctctgtgtga ggctttaacc ttagcgaccg ggcctatctc cacattgtgg 
7441 gaaggaaatc cagggaggtt ttggaacact accattgcag tgtcaatggc taacattttt 
7501 agagggagtt acttggccgg agctggactt ctcttttcca tcatgaagaa cacaaccaac 
7561 acgagaaggg gaactggcaa cataggagag acgcttggag agaaatggaa aagccgattg 
7621 aacgcattgg ggaaaagtga attccagatc tacaagaaaa gtggaatcca ggaagtggat 
7681 agaaccttag caaaagaagg cattaaaaga ggagaaacgg accatcacgc tgtgtcgcga 
7741 ggctcagcaa aactgagatg gttcgtcgag agaaatatgg tcacaccaga agggaaagta 
7801 gtggacctcg gttgcggcag aggaggctgg tcatactatt gtgggggact aaagaatgta 
7861 agagaagtca aaggcctaac aaaaggagga ccaggacatg aagaacccat ccccatgtca 
7921 acatatgggt ggaatctagt acgtcttcaa agtggagttg acgttttctt cactccgcca 
7981 gaaaagtgtg acacattgtt gtgtgacata ggggagtcgt caccaaatcc cacggtagaa 
8041 gcaggacgaa cactcagagt ccttaactta gtggaaaatt ggttgaacaa caacacccaa 
8101 ttttgcataa aggttctcaa cccatacatg ccctcagtca tagaaaaaat ggaagcacta 
8161 caaaggaaat atggaggagc cttagtgagg aatccacttt cacgaaactc cacacatgag 
8221 atgtactggt tatccaatgc ctccgggaac atagtgtcat cagtgaacat gatttcaagg 
8281 atgttgatca acagattcac aatgagacac aagaaagcca cttacgagcc agatgtagac 
8341 ctcggaagcg gaacccgcaa catcggaatt gaaagtgaga taccaaacct agacataatc 
8401 gggaaaagaa tagaaaaaat aaaacaagag catgaaacat catggcacta tgaccaagac 
8461 cacccataca aaacgtgggc ttaccatggc agctatgaaa caaaacaaac tggatcagca 
8521 tcatccatgg gtaacggagt ggtcagactg ctgacaaaac cttgggacgt cgtccccatg 
8581 gtaacacaga tggcaatgac agacacgact ccatttggac aacagcgcgt ttttaaagaa 
8641 aaagtggaca cgagaaccca agaaccgaaa gaaggcacaa agaaactaat gaaaatcacg 
8701 gcagagtggc tttggaaaga actagggaag aaaaagacac ctaggatgtg cactagagaa 
8761 gaattcacaa gaaaggtgag aagcaatgca gccttggggg ccatattcac tgatgagaac 
8821 aagtggaagt cggcacgtga ggctgttgaa gatagtaggt tttgggagct ggttgacaag 
8881 gaaaggaatc tccatcttga aggaaagtgt gaaacatgtg tgtataacat gatgggaaaa 
8941 agagagaaga agctagggga gttcggcaag gcaaaaggca gcagagccat atggtacatg 
9001 tggcttggag cacgcttctt agagtttgaa gccctaggat tcttgaatga agatcactgg 
9061 ttctccagag agaactcctt gagtggagtg gaaggagaag ggctgcacaa gctaggttac 
9121 attttaagag acgtgagcaa gaaagaggga ggagcaatgt atgccgatga caccgcagga 
9181 tgggacacaa gaatcacact agaagaccta aaaaatgaag aaatggtaac aaaccacatg 
9241 gaaggagaac acaagaaact agccgaggcc attttcaaat taacgtacca aaacaaggtg 
9301 gtgcgtgtgc aaagaccaac accaagaggc acagtaatgg atatcatatc gagaagagac 
9361 caaagaggta gtggacaagt tggtacctat ggactcaata ctttcaccaa tatggaagcc 
9421 caactaatca gacagatgga gggagaagga gtcttcaaaa gcattcagca cctgacagtc 
9481 acagaagaaa tcgccgtgca aaactggtta gcaagagtag ggcgcgaaag gttatcaaga 
9541 atggccatca gtggagatga ttgtgttgtg aaacctttag atgacaggtt cgcaagcgct 
9601 ttaacagctc taaatgacat gggaaaggtt aggaaagaca tacaacaatg ggaaccttca 
9661 agaggatgga acgattggac acaagtgccc ttctgttcac accatttcca tgagttaatc 
9721 atgaaagacg gccgcgtact tgtagttcca tgcagaaacc aagatgaact gattggtaga 
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9781 gcccgaattt cccaaggagc tgggtggtct ttgcgagaga cggcctgttt ggggaagtcc 
9841 tacgcccaaa tgtggagctt gatgtacttc cacagacgtg acctcaggct ggcggctaat 
9901 gctatttgct cggcagtccc atcacattgg gttccaacaa gtagaacaac ctggtccata 
9961 cacgccaaac atgaatggat gacaacggaa gacatgctga cagtctggaa cagggtgtgg 
10021 attcaagaaa acccatggat ggaagacaaa actccagtgg aatcatggga ggaaatccca 
10081 tacttgggga aaagagaaga ccaatggtgc ggctcattga ttgggctaac aagcagggcc 
10141 acctgggcaa agaacatcca aacagcaata aatcaagtta gatcccttat aggcaatgag 
10201 gaatacacag attacatgcc atccatgaaa agattcagaa aagaagagga agaggcagga 
10261 gtcctgtggt agaaggcaaa actaacatga aacaaggcta gaagtcaggt cggattaagc 
10321 catagtacgg aaaaaactat gctacctgtg agccccgtcc aaggacgtta aaagaagtca 
10381 ggccattaca aatgccatag cttgagtaaa ctgtgcagcc tgtagctcca cctgagaagg 
10441 tgtaaaaaat ctgggaggcc acaaaccatg gaagctgtac gcatggcgta gtggactagc 
10501 ggttagagga gacccctccc ttacaaatcg cagcaacaat gggggcccaa ggtgagatga 
10561 agctgtagtc tcactggaag gactagaggt tagaggagac ccccccaaaa caaaaaacag 
10621 catattgacg ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca 
10681 gaacgccaga aaatggaatg gtgctgttga atcaacaggt tct 
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APPENDIX 3- QIAGEN QIAquick Gel Extraction Protocol 
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APPENDIX 4- QIAGEN QIAprep Miniprep Protocol 
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